Recently, the Category 1.1 innovative traditional Chinese medicine Tongluo Mingmu Capsules of Shijiazhuang Yiling Pharmaceutical Co., Ltd. is approved for marketing by China NMPA.

　　This drug has undergone a randomized, double blind, double simulated, parallel controlled multicenter clinical trial of calcium dobesilate capsules. The results of clinical trial study showed that after 12 weeks of treatment, the spot and patch hemorrhage of moderate nonproliferative diabetic retinopathy in the test group was superior to that in the control group. The drug can remove blood stasis and dredge collaterals, replenish qi and nourish yin, stop bleeding and brighten eyes. It is indicated for the symptoms related to blood stasis and obstruction of collaterals in moderate nonproliferative retinopathy caused by type 2 diabetes, and spot and patch hemorrhage of fundus and dryness of eyes caused by deficiency of both qi and yin. The marketing of this drug provides new treatment options for patients with the above-mentioned symptoms.